Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 12, Issue 2, Pages 101-105

No evidence for a putative involvement of platelet-activating factor in systemic lupus erythematosus without active nephritis

1UMR CNRS 6101, Laboratoire d'Immunologie, Faculté de Médecine, 2 rue Dr Marcland, Limoges 87025, France
2Service de Médecine Interne, CHU Dupuytren, Limoges, France

Copyright © 2003 Hindawi Publishing Corporation. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Background: Platelet-activating factor (PAF) seems to be implicated in systemic lupus erythematosus (SLE) patients with associated renal diseases.Aims: In this study, we ensured the role of PAF in SLE patients without renal complications.

Methods: Blood PAF and acetylhydrolase activity, plasma soluble phospholipase A2, and the presence of antibodies against PAF were investigated in 17 SLE patients without active nephritis and in 17 healthy controls.

Results: Blood PAF levels were not different (P=0.45) between SLE patients (6.7±2.8 pg/ml) and healthy subjects (9.6±3.1 pg/ml). Plasma acetylhydrolase activity (the PAF-degrading enzyme) was significantly (P=0.03) elevated in SLE patients (57.8±6.4 nmol/min/ml) as compared with controls (37.9±2.6 nmol/min/ml). Plasma soluble phospholipase A2 (the key enzyme for PAF formation) was not different (P=0.6) between SLE patients (59.1±5.1 U/ml) and controls (54.7±2.4 U/ml). Antibodies against PAF were detected only in 3/17 SLE patients. Flow cytometry analysis did not highlight PAF receptors on circulating leukocytes of SLE patients.

Conclusion: This clinical study highlights no evidence for a putative important role of PAF in SLE patients without active nephritis.